




Corporate Press Release

3rd October 2011

Norgine Welcomes Their New Chief Development Officer



Norgine is delighted to announce that Dr Donna McVey has joined Norgine as Chief Development Officer from 3rd October 2011.

Donna will head up Norgine's Development activities covering Medical and Regulatory Affairs, five Therapy Area Development Teams, Pharmaceutical and Preclinical Development, Intellectual Property, Global Pharmacovigilance and Global Quality. As such she will have responsibility for developing Norgine's pipeline, managing and further developing current products and maintaining Norgine's product licences and trial applications.

After graduating with her MB.BS and a B.Sc in Clinical Pharmacology, Donna worked for six years in the National Health Service. Her career in the Pharmaceutical Industry spans over 20 years, working at a senior level within major pharma companies and also in strategic consultancy. Donna joins Norgine from Reckitt Benckiser where she worked as Director of Global Regulatory and Medical Affairs.

ENDS

About Norgine

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine's net product sales were €258 million. The Company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

For more information: www.norgine.com

Norgine Contact
Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com